Who are OPC-262's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NPC-16 Standard Dosing Regimen Group, SPM 962, SPMC 2, NPC-16 Continuous Dosing Regimen Group, Aplause®, allo-APZ2-OTS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/opc-262.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

OPC-262 — Competitive Intelligence Brief

OPC-262 (OPC-262) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1PR1 inhibitor. Area: Immunology.

phase 3 S1PR1 inhibitor S1PR1 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

OPC-262 (OPC-262) — Kyowa Kirin Co., Ltd.. OPC-262 is a selective and potent inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
OPC-262 TARGET	OPC-262	Kyowa Kirin Co., Ltd.	phase 3	S1PR1 inhibitor	S1PR1
NPC-16 Standard Dosing Regimen Group	NPC-16 Standard Dosing Regimen Group	Nobelpharma	phase 3	S1P receptor modulator	S1PR1
SPM 962	SPM 962	Otsuka Pharmaceutical Co., Ltd.	phase 3	S1P receptor modulator	S1PR1
SPMC 2	SPMC 2	Korea University Anam Hospital	phase 3	Sphingosine-1-phosphate receptor 1 (S1PR1) modulator	S1PR1
NPC-16 Continuous Dosing Regimen Group	NPC-16 Continuous Dosing Regimen Group	Nobelpharma	phase 3	S1P receptor modulator	S1PR1
Aplause®	Aplause®	Phytopharm Consulting Brazil	phase 3	S1P receptor modulator	S1PR1
allo-APZ2-OTS	allo-APZ2-OTS	RHEACELL GmbH & Co. KG	phase 3	S1P receptor modulator	S1PR1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1PR1 inhibitor class)

AbbVie · 1 drug in this class
Kyowa Kirin Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OPC-262 — Competitive Intelligence Brief. https://druglandscape.com/ci/opc-262. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab